Johnson & Johnson has produced the most convincing data to date that its combination of Rybrevant and Lazcluze could replace ...

New study results presented at the European Lung Cancer Congress (ELCC) 2025, March 26 to 29, demonstrate the role of AstraZeneca's TAGRISSO® (osimertinib), as monotherapy and as the backbone for ...

Professor Virginia Harrison, EGFR Positive UK, said ... 95% CI 0.57-0.97, maturity 41%), with consistent results across all prespecified subgroups. The trial will continue to assess OS as ...

New study results presented at the European Lung Cancer Congress (ELCC) 2025, 26 to 29 March, demonstrate the role of AstraZeneca’s Tagrisso (osimertinib), as monotherapy and as the backbone for novel ...

Weight fluctuation was associated with a greater risk for diabetic kidney disease progression among individuals with type 1 diabetes.

EVM14 received U.S. FDA clearance for its IND application, becoming Everest's first internally discovered program, and the first mRNA therapeutic cancer vaccine to be cleared ...

The HER3-directed ADC will be tested in patients whose disease had progressed despite earlier treatment with EGFR inhibitors, including third-generation drugs like AZ's Tagrisso (osimertinib).

Professor Virginia Harrison, EGFR Positive UK, said ... 95% CI 0.57-0.97, maturity 41%), with consistent results across all prespecified subgroups. The trial will continue to assess OS as a key ...

Advanced lung cancer, which has spread (metastasized) from the primary tumor to distant organs, is associated with lower survival rates. That's because lung cancer becomes more difficult to treat as ...

safe and convenient treatment for patients with EGFR-mutated lung cancer across stages and lines of treatment." Susan Galbraith, Executive Vice President, Oncology Hematology R&D, AstraZeneca ...

Trichy: MDMK MP Durai Vaiko has urged the Union govt to lift procurement restrictions imposed on Bhel to source materials ...